Rep. Lloyd Doggett

Maddy summaryHR 3277, the Ensuring Lasting Smiles Act, requires group health plans and health insurance issuers to cover medically necessary outpatient and inpatient treatments for congenital anomalies or birth defects primarily affecting the eyes, ears, teeth, mouth, or jaw. This includes reconstructive procedures, dental/orthodontic support during treatment, and follow-up care, but excludes purely cosmetic surgery not tied to a medical diagnosis. Cost-sharing (like copays) for these services must not be stricter than for other medical benefits. The law takes effect for plan years beginning January 1, 2026, and mandates insurers to provide notice about this coverage to beneficiaries.

Maddy summaryThe ETHIC Act (HR 3269) limits how many patents pharmaceutical companies can assert in lawsuits against generic drug and biosimilar manufacturers. Specifically, it prohibits a company from claiming more than one patent per "Patent Group" (commonly owned patents linked through disclaimers) in an infringement case involving a generic drug applicant or biosimilar product. This directly affects generic drug makers (under FDA's 505(b)(2) or 505(j) pathways) and biosimilar developers (under the Public Health Service Act), reducing the ability of brand-name companies to use stacked patents to delay competition. The law applies to applications submitted after its enactment date.

Maddy summaryHR 3306, the Truth in Tariffs Act, requires retailers selling goods to U.S. consumers to clearly display the portion of a product's price caused by applicable tariffs (called a "tariff surcharge"). This applies to most retailers but exempts small businesses as defined by the Small Business Act. The Federal Trade Commission (FTC) will enforce this rule, treating violations as unfair or deceptive practices under existing law, with penalties similar to those for other FTC violations. The law takes effect 30 days after enactment, covering tariffs imposed by the President after January 20, 2025.

Maddy summaryThis bill amends the Higher Education Act to clarify eligibility for Public Service Loan Forgiveness (PSLF). It corrects a technical wording error in the law that previously required borrowers to be *currently employed* in public service at the time of application. The change specifies that borrowers only need to have *completed* 10 years (120 payments) of qualifying public service employment to qualify. This directly affects federal student loan borrowers working in government or nonprofit roles who were previously disqualified due to the outdated wording. The amendment removes a barrier preventing eligible borrowers from receiving loan forgiveness they earned.

Maddy summaryHR 3243, the Therapeutic Fraud Prevention Act of 2025, bans the provision of paid conversion therapy aimed at changing a person's sexual orientation or gender identity, and prohibits advertising such therapy as effective, safe, or without risk. It directly affects LGBTQ+ individuals and their families who might be targeted by these practices, as professionals have determined conversion therapy is ineffective and harmful. The law treats violations as deceptive acts under consumer protection laws, empowering the Federal Trade Commission and state attorneys general to enforce it through civil actions. It explicitly excludes legitimate gender transition support and non-discriminatory counseling from the ban.

Maddy summaryThis bill creates annual emergency grants for farm workers affected by covered disasters. It directly helps migrant and seasonal farm workers who lose income or cannot work due to events like hurricanes, wildfires, pandemics, or extreme weather. Grants fund immediate relief (food, shelter), rebuild community capacity, and support long-term resilience against future disasters. Eligible organizations, including farm worker groups or qualified nonprofits, receive funds to distribute aid without time limits.

Maddy summaryHR 3184, the PFAS Alternatives Act, funds research to develop turnout gear (firefighter safety clothing) without harmful PFAS chemicals, directly affecting firefighters who wear this gear. It authorizes $25 million annually (2025-2029) for grants to eligible organizations to research and test PFAS-free gear, requiring partnerships with firefighting groups to translate findings into practice. The bill also allocates $2 million yearly (2027-2031) for training programs on safe gear use and decontamination. Its goal is to reduce firefighters' exposure to chemicals linked to occupational illnesses during operations.

Maddy summaryThe MEGOBARI Act (HR 36) is a U.S. legislative proposal that aims to strengthen Georgia's democratic development and Euro-Atlantic integration. It directs the U.S. Secretary of State to suspend the U.S.-Georgia Strategic Partnership Commission until Georgia meets specific democratic standards, including respecting citizens' democratic wishes and advancing EU/NATO membership. The bill establishes potential sanctions against Georgian officials who block Euro-Atlantic integration or undermine Georgia's sovereignty, requiring the President to determine if officials have engaged in significant corruption or actions against Georgia's territorial integrity. Additionally, it mandates reports on Russian intelligence assets in Georgia and a 5-year U.S. strategy for bilateral relations, with the Act set to sunset after 5 years from enactment.

Maddy summaryThis bill requires U.S. Customs and Border Protection (CBP), U.S. Immigration and Customs Enforcement (ICE), and other deputized immigration officers to visibly identify themselves during enforcement actions. Specifically, it mandates that officers display a 12-inch by 6-inch agency identifier on their uniform front or back, ensuring it remains unobscured by armor or accessories. The requirement applies during all "time of action" activities, such as patrols, raids, arrests, or warrant service. The bill directly affects immigration enforcement personnel by standardizing their visible identification during interactions with the public.

Affordable and Safe Prescription Drug Importation Act of 2025 This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported. Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs. The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements. The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin. Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS. Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription.